InflaRx N.V. (NASDAQ:IFRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $6.20.

Several research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of InflaRx in a research report on Tuesday, October 14th. HC Wainwright assumed coverage on InflaRx in a research report on Tuesday, September 2nd. They set a “buy” rating and a $6.00 price objective on the stock.

InflaRx Price Performance

IFRX stock opened at $1.38 on Tuesday. The stock has a market capitalization of $92.64 million, a price-to-earnings ratio of -1.72 and a beta of 1.40. The business’s fifty day moving average price is $1.38 and its two-hundred day moving average price is $1.18. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $2.82.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.02 million. Research analysts expect that InflaRx will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in InflaRx in the first quarter valued at about $38,000. DAFNA Capital Management LLC acquired a new position in InflaRx in the first quarter valued at about $459,000. Cubist Systematic Strategies LLC raised its stake in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares in the last quarter. 683 Capital Management LLC raised its stake in InflaRx by 26.8% in the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in InflaRx in the first quarter valued at about $766,000. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.